Oppenheimer Downgrades Biohaven Pharmaceutical to Perform, Lowers Price Target to $51

Oppenheimer analyst Esther Rajavelu downgrades Biohaven Pharmaceutical (NYSE:BHVN) from Outperform to Perform and lowers the price target from $67 to $51.

Benzinga · 02/10/2020 15:19

Oppenheimer analyst Esther Rajavelu downgrades Biohaven Pharmaceutical (NYSE:BHVN) from Outperform to Perform and lowers the price target from $67 to $51.